<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is growing support for the hypothesis that <z:hpo ids='HP_0001513'>obesity</z:hpo> is an inflammatory condition leading to <z:hpo ids='HP_0011010'>chronic</z:hpo> activation of the innate immune system, which ultimately causes progressive impairment of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental studies in animals and evidence from prospective and longitudinal studies in humans are consistent with an etiologic role of subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, primarily as a mediator of <z:hpo ids='HP_0001513'>obesity</z:hpo>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the exact chain of molecular events linking <z:e sem="disease" ids="C1257763" disease_type="Disease or Syndrome" abbrv="">overnutrition</z:e>, activation of the innate immune system, and impairment of insulin signaling in peripheral tissues remains incompletely understood </plain></SENT>
<SENT sid="3" pm="."><plain>Notwithstanding this limitation, treating the underlying subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> may constitute a novel approach to prevention and/or treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>